jRCT2051260041招募中不适用
A Phase II Clinical Trial of Olutasidenib in Patients with Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia
未提供0 个研究点目标入组 3 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Japanese patients who personally provide written informed consent to participate in this
- •clinical trial
- •Patients with a confirmed diagnosis of AML based on WHO classification (2022 edition) (except acute promyelocytic leukemia with t (15:17) translocation).
- •Patients with relapsed or refractory AML who may or may not have undergone allogeneic hematopoietic stem cell transplantation.
- •Patients with IDH1 gene mutation confirmed by central confirmation after relapse or refractoriness
排除标准
- •Patients with known IDH2 mutations or prior treatment with IDH2 inhibitors
- •Patients who are intolerant to IDH1 inhibitors
- •Patients who are judged ineligible for the clinical trial by the principal investigator or subinvestigator
研究者
相似试验
招募中
2 期
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating AgentAcute Myeloid LeukemiaNCT07304011University of California, Davis28
进行中（未招募）
1 期
Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT07411586M.D. Anderson Cancer Center32
招募中
2 期
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received VenetoclaxNCT07471841Timothy Pardee25
尚未招募
2 期
A Trial of Upadacitinib for Non-responsive Eosinophilic EsophagitisEosinophilic Esophagitis (EoE)EoEEosinophilic EsophagitisNCT07588568University of North Carolina, Chapel Hill52
招募中
1 期
Phase I trial with 177Lu-DOTA-TATE and olaparib in somatostatin receptor positive tumours2024-512463-31-00Vaestra Goetalandsregionen18